BRPI1013843A2 - pirrolo[2,3.b]piridinas que inibem raf proteína quinase - Google Patents

pirrolo[2,3.b]piridinas que inibem raf proteína quinase

Info

Publication number
BRPI1013843A2
BRPI1013843A2 BRPI1013843A BRPI1013843A BRPI1013843A2 BR PI1013843 A2 BRPI1013843 A2 BR PI1013843A2 BR PI1013843 A BRPI1013843 A BR PI1013843A BR PI1013843 A BRPI1013843 A BR PI1013843A BR PI1013843 A2 BRPI1013843 A2 BR PI1013843A2
Authority
BR
Brazil
Prior art keywords
pyridines
pyrrolo
protein kinase
raf protein
inhibit raf
Prior art date
Application number
BRPI1013843A
Other languages
English (en)
Inventor
Guoxian Wu
Hanna Cho
Phabha N Ibrahim
Sougyuan Shi
Wayne Spevak
Original Assignee
Plexxikon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42236712&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI1013843(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Plexxikon Inc filed Critical Plexxikon Inc
Publication of BRPI1013843A2 publication Critical patent/BRPI1013843A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
BRPI1013843A 2009-05-06 2010-05-04 pirrolo[2,3.b]piridinas que inibem raf proteína quinase BRPI1013843A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17605409P 2009-05-06 2009-05-06
PCT/US2010/033571 WO2010129567A1 (en) 2009-05-06 2010-05-04 Pyrrolo [2, 3. b] pyridines which inhibit raf protein kinase

Publications (1)

Publication Number Publication Date
BRPI1013843A2 true BRPI1013843A2 (pt) 2016-04-12

Family

ID=42236712

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1013843A BRPI1013843A2 (pt) 2009-05-06 2010-05-04 pirrolo[2,3.b]piridinas que inibem raf proteína quinase

Country Status (23)

Country Link
US (3) US20120122860A1 (pt)
EP (2) EP2427462A1 (pt)
JP (2) JP2012526128A (pt)
KR (1) KR20140014386A (pt)
CN (1) CN102459262A (pt)
AR (1) AR076749A1 (pt)
AU (1) AU2010246005A1 (pt)
BR (1) BRPI1013843A2 (pt)
CA (1) CA2759997A1 (pt)
CL (1) CL2011002739A1 (pt)
CR (1) CR20110562A (pt)
EC (1) ECSP11011437A (pt)
IL (1) IL215908A0 (pt)
MA (1) MA34042B1 (pt)
MX (1) MX2011011737A (pt)
NI (1) NI201100189A (pt)
NO (1) NO20111508A1 (pt)
PE (1) PE20120518A1 (pt)
RU (1) RU2011149485A (pt)
SG (1) SG175810A1 (pt)
TW (1) TW201041888A (pt)
WO (2) WO2010129567A1 (pt)
ZA (1) ZA201108124B (pt)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007002433A1 (en) * 2005-06-22 2007-01-04 Plexxikon, Inc. Pyrrolo [2, 3-b] pyridine derivatives as protein kinase inhibitors
WO2008063888A2 (en) 2006-11-22 2008-05-29 Plexxikon, Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
CN101808994B (zh) 2007-07-17 2013-05-15 普莱希科公司 用于激酶调节的化合物和方法以及其适应症
WO2009143018A2 (en) 2008-05-19 2009-11-26 Plexxikon, Inc. Compounds and methods for kinase modulation, and indications therefor
US9447089B2 (en) 2009-04-03 2016-09-20 Plexxikon Inc. Compositions and uses thereof
US8329724B2 (en) 2009-08-03 2012-12-11 Hoffmann-La Roche Inc. Process for the manufacture of pharmaceutically active compounds
UA105813C2 (uk) 2009-11-06 2014-06-25 Плексікон, Інк. Сполуки-інгібітори кіназ та фармацевтична композиція (варіанти)
MY156210A (en) 2009-11-18 2016-01-29 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
BR112012015745A2 (pt) * 2009-12-23 2016-05-17 Plexxikon Inc compostos e métodos para a modulação de quinase, e indicações dos mesmos
TWI510487B (zh) 2010-04-21 2015-12-01 Plexxikon Inc 用於激酶調節的化合物和方法及其適應症
GB201007286D0 (en) 2010-04-30 2010-06-16 Astex Therapeutics Ltd New compounds
GB201020179D0 (en) 2010-11-29 2011-01-12 Astex Therapeutics Ltd New compounds
JP6112512B2 (ja) * 2010-12-01 2017-04-12 レクシ ファーマ インコーポレイテッド 難治性癌を治療するための方法
US8889684B2 (en) * 2011-02-02 2014-11-18 Boehringer Ingelheim International Gmbh Azaindolylphenyl sulfonamides as serine/threonine kinase inhibitors
WO2012106559A1 (en) * 2011-02-02 2012-08-09 Translational Genomics Research Institute Biomarkers and methods of use thereof
AU2012214762B2 (en) * 2011-02-07 2015-08-13 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
TWI558702B (zh) * 2011-02-21 2016-11-21 普雷辛肯公司 醫藥活性物質的固態形式
CN103476943A (zh) 2011-03-10 2013-12-25 普罗维克图斯药品公司 用于增强治疗癌症的局部和全身性免疫调节疗法的组合
WO2012138809A1 (en) * 2011-04-05 2012-10-11 Dawei Zhang Heterocyclic compounds as kinase inhibitors
BR112013029163A2 (pt) 2011-05-17 2017-01-31 Plexxikon Inc modulação quinase e indicações dos mesmos
CA2846574C (en) * 2011-08-26 2020-07-07 Neupharma, Inc. Quinoxaline sulfonamide derivates for use as kinase inhibitors
CN102993199A (zh) * 2011-09-09 2013-03-27 山东轩竹医药科技有限公司 杂环取代的吡啶并吡咯激酶抑制剂
CA2848506C (en) 2011-09-14 2020-07-21 Neupharma, Inc. Certain chemical entities, compositions, and methods
WO2013043935A1 (en) 2011-09-21 2013-03-28 Neupharma, Inc. Certain chemical entites, compositions, and methods
WO2013049701A1 (en) 2011-09-30 2013-04-04 Neupharma, Inc. Certain chemical entities, compositions, and methods
GB201118675D0 (en) 2011-10-28 2011-12-14 Astex Therapeutics Ltd New compounds
GB201118652D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118656D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118654D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
WO2013112950A2 (en) 2012-01-25 2013-08-01 Neupharma, Inc. Certain chemical entities, compositions, and methods
US9358235B2 (en) 2012-03-19 2016-06-07 Plexxikon Inc. Kinase modulation, and indications therefor
JP6013029B2 (ja) * 2012-05-25 2016-10-25 千葉県 抗癌剤
GB201209613D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
GB201209609D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
US9150570B2 (en) * 2012-05-31 2015-10-06 Plexxikon Inc. Synthesis of heterocyclic compounds
JO3407B1 (ar) 2012-05-31 2019-10-20 Eisai R&D Man Co Ltd مركبات رباعي هيدرو بيرازولو بيريميدين
US9221815B2 (en) * 2012-07-03 2015-12-29 Ratiopharm Gmbh Solid state form of vemurafenib choline salt
DE102012016908A1 (de) * 2012-08-17 2014-02-20 Aicuris Gmbh & Co. Kg Tris-(Hetero)Aryl-Pyrazole und ihre Verwendung
TWI601725B (zh) 2012-08-27 2017-10-11 加拓科學公司 取代的氮雜吲哚化合物及其鹽、組合物和用途
JP6318156B2 (ja) 2012-09-06 2018-04-25 プレキシコン インコーポレーテッドＰｌｅｘｘｉｋｏｎ Ｉｎｃ． キナーゼをモジュレートするための化合物および方法、ならびにその指標
EP2897618B1 (en) 2012-09-24 2021-11-17 Neupharma, Inc. Certain chemical entities, compositions, and methods
CN105712992B (zh) * 2012-09-29 2018-10-26 上海科州药物研发有限公司 作为cMet抑制剂的化合物及其制备方法和用途
US9725421B2 (en) 2012-11-12 2017-08-08 Neupharma, Inc. Substituted quinoxalines as B-raf kinase inhibitors
AU2013348116A1 (en) 2012-11-20 2015-06-11 Principia Biopharma Inc. Azaindole derivatives as JAK3 inhibitors
US9676748B2 (en) 2012-12-21 2017-06-13 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
MX2015009270A (es) 2013-01-18 2015-10-30 Hoffmann La Roche Pirazoles sustituidos en posicion 3 y uso de los mismos como inhibidores de la cinasa cremallera de leucinas dual (dlk).
EP2970270A1 (en) 2013-03-14 2016-01-20 ratiopharm GmbH Solid state forms of vemurafenib hydrochloride
US20140303121A1 (en) 2013-03-15 2014-10-09 Plexxikon Inc. Heterocyclic compounds and uses thereof
JP6325078B2 (ja) 2013-03-15 2018-05-16 プレキシコン インコーポレーテッドＰｌｅｘｘｉｋｏｎ Ｉｎｃ． ヘテロ環式化合物およびその使用
GB201307577D0 (en) 2013-04-26 2013-06-12 Astex Therapeutics Ltd New compounds
EP3004060B1 (en) * 2013-05-30 2019-11-27 Plexxikon Inc. Compounds for kinase modulation, and indications therefor
WO2015075749A1 (en) * 2013-11-22 2015-05-28 Laurus Labs Private Limited Novel processes for the preparation of vemurafenib
CZ2013943A3 (cs) 2013-11-27 2015-06-03 Zentiva, K.S. Krystalické formy vemurafenibu
WO2015134536A1 (en) 2014-03-04 2015-09-11 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
AU2015238301B2 (en) 2014-03-26 2020-06-25 Astex Therapeutics Ltd Combinations
JO3512B1 (ar) 2014-03-26 2020-07-05 Astex Therapeutics Ltd مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز
KR102479696B1 (ko) 2014-03-26 2022-12-22 아스텍스 테라퓨틱스 리미티드 Fgfr 억제제 및 igf1r 억제제의 조합물
NO2714752T3 (pt) * 2014-05-08 2018-04-21
JP6832846B2 (ja) 2014-09-15 2021-02-24 プレキシコン インコーポレーテッドＰｌｅｘｘｉｋｏｎ Ｉｎｃ． ヘテロ環化合物およびその用途
JOP20200201A1 (ar) 2015-02-10 2017-06-16 Astex Therapeutics Ltd تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين
US10478494B2 (en) 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
US10160755B2 (en) 2015-04-08 2018-12-25 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
CZ2015250A3 (cs) 2015-04-14 2016-10-26 Zentiva, K.S. Amorfní formy vemurafenibu
WO2017019804A2 (en) 2015-07-28 2017-02-02 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
GB201516504D0 (en) 2015-09-17 2015-11-04 Astrazeneca Ab Imadazo(4,5-c)quinolin-2-one Compounds and their use in treating cancer
CN113754656A (zh) 2015-09-21 2021-12-07 普莱希科公司 杂环化合物及其应用
BR112018005637B1 (pt) 2015-09-23 2023-11-28 Janssen Pharmaceutica Nv Compostos derivados de quinoxalina, quinolina e quinazolinona,composições farmacêuticas que os compreende, e uso dos referidos compostos
US11542247B2 (en) 2015-09-23 2023-01-03 Janssen Pharmaceutica Nv Bi-heteroaryl substitute 1,4-benzodiazepines and uses thereof for the treatment of cancer
BR112018011475A2 (pt) 2015-12-07 2018-12-04 Plexxikon Inc compostos e métodos para modulação de quinase e indicação para a mesma
US10160747B2 (en) 2016-03-16 2018-12-25 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
US10195188B2 (en) 2016-06-13 2019-02-05 Chemocentryx, Inc. Method of treating pancreatic cancer
WO2017218544A1 (en) * 2016-06-13 2017-12-21 Chemocentryx, Inc. Methods of treating pancreatic cancer
CN107722013B (zh) * 2016-08-11 2021-01-12 中国科学院上海药物研究所 去氮嘌呤类化合物及其药物组合物、制备方法和用途
TW201815766A (zh) 2016-09-22 2018-05-01 美商普雷辛肯公司 用於ｉｄｏ及ｔｄｏ調節之化合物及方法以及其適應症
MX2021014356A (es) 2016-11-23 2022-11-24 Chemocentryx Inc Metodo para tratar glomeruloesclerosis segmentaria focal.
AU2017395023B2 (en) 2016-12-23 2022-04-07 Plexxikon Inc. Compounds and methods for CDK8 modulation and indications therefor
AU2018209164B2 (en) * 2017-01-17 2021-11-04 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
AU2018237047A1 (en) 2017-03-20 2019-10-17 Plexxikon Inc. Crystalline forms of 4-(1-(1,1-di(pyridin-2-yl)ethyl)-6-(3,5-dimethylisoxazol-4-yl)-1H- pyrrolo[3,2-b]pyridin-3-yl)benzoic acid that inhibits bromodomain
WO2018226846A1 (en) 2017-06-07 2018-12-13 Plexxikon Inc. Compounds and methods for kinase modulation
TWI805599B (zh) 2017-07-25 2023-06-21 美商第一三共公司 激酶調節化合物之調配物
WO2019075086A1 (en) 2017-10-11 2019-04-18 Chemocentryx, Inc. TREATMENT OF FOCAL SEGMENTAL GLOBEROSCLEROSIS WITH CCR2 ANTAGONISTS
EP3694855A1 (en) 2017-10-13 2020-08-19 Plexxikon Inc. Solid forms of a compound for modulating kinases
CN112165958A (zh) 2017-10-27 2021-01-01 普莱希科公司 调制激酶的化合物的制剂
EP3737382A1 (en) * 2018-01-10 2020-11-18 Cura Therapeutics, LLC Pharmaceutical compositions comprising phenylsulfonamides, and their therapeutic applications
CA3089678A1 (en) 2018-01-31 2019-08-08 Heparegenix Gmbh Protein kinase mkk4 inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
CN112119072A (zh) 2018-03-20 2020-12-22 普莱希科公司 用于ido和tdo调节的化合物和方法，以及其适应症
US11731968B2 (en) 2018-06-21 2023-08-22 Heparegenix Gmbh Tricyclic protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
WO2020016243A1 (en) * 2018-07-16 2020-01-23 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA05002444A (es) 2002-09-06 2005-09-30 Insert Therapeutics Inc Polimeros a base de ciclodextrina para el suministro de agentes terapeuticos.
WO2007002433A1 (en) * 2005-06-22 2007-01-04 Plexxikon, Inc. Pyrrolo [2, 3-b] pyridine derivatives as protein kinase inhibitors
DE102005034406A1 (de) 2005-07-22 2007-02-01 Ratiopharm Gmbh Neue Salze von Rosiglitazon
WO2008063888A2 (en) 2006-11-22 2008-05-29 Plexxikon, Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
GB0624084D0 (en) * 2006-12-01 2007-01-10 Selamine Ltd Ramipril amino acid salts
PE20121126A1 (es) 2006-12-21 2012-08-24 Plexxikon Inc Compuestos pirrolo [2,3-b] piridinas como moduladores de quinasa
WO2008079909A1 (en) 2006-12-21 2008-07-03 Plexxikon, Inc. Pyrrolo [2,3-b] pyridines as kinase modulators
CN101808994B (zh) * 2007-07-17 2013-05-15 普莱希科公司 用于激酶调节的化合物和方法以及其适应症

Also Published As

Publication number Publication date
KR20140014386A (ko) 2014-02-06
MA34042B1 (fr) 2013-03-05
TW201041888A (en) 2010-12-01
JP2012526127A (ja) 2012-10-25
CN102459262A (zh) 2012-05-16
SG175810A1 (en) 2011-12-29
CL2011002739A1 (es) 2012-04-09
ECSP11011437A (es) 2011-12-30
WO2010129567A1 (en) 2010-11-11
NI201100189A (es) 2012-01-11
US20100286142A1 (en) 2010-11-11
IL215908A0 (en) 2012-01-31
MX2011011737A (es) 2011-12-08
AR076749A1 (es) 2011-07-06
EP2427462A1 (en) 2012-03-14
CR20110562A (es) 2012-02-09
US8198273B2 (en) 2012-06-12
JP2012526128A (ja) 2012-10-25
US20120245174A1 (en) 2012-09-27
RU2011149485A (ru) 2013-06-20
PE20120518A1 (es) 2012-05-24
NO20111508A1 (no) 2011-12-02
EP2427433A1 (en) 2012-03-14
ZA201108124B (en) 2014-04-30
WO2010129570A1 (en) 2010-11-11
US20120122860A1 (en) 2012-05-17
AU2010246005A1 (en) 2011-12-01
CA2759997A1 (en) 2010-11-11

Similar Documents

Publication Publication Date Title
BRPI1013843A2 (pt) pirrolo[2,3.b]piridinas que inibem raf proteína quinase
NO2021006I1 (no) Quofenix, delafloksacin
SI2201012T1 (sl) Derivati pirolo(2,3-D)pirimidina kot inhibitorji proteina kinaze B
BRPI0814466A2 (pt) Método.
BRPI0811434A2 (pt) imidazopiridazinas como inibidores de pi3k lipídeo cinase.
BRPI0918430A2 (pt) 4-fenil-1h-pirazóis inseticidas.
IT1394288B1 (it) Immunogeni di proteine che legano il fattore h.
UY33125A (es) Diaza-espiro-[5,5]-undecanos
IT1393413B1 (it) Composizione pesticida.
BRPI0922477A2 (pt) transportador.
IT1396642B1 (it) Statore.
IT1393582B1 (it) Composizione pesticida.
BRPI1011720A2 (pt) compostos de 1,1,1- tri-flúor-2 hidróxi-propila.
DK2241564T3 (da) 3,8-diaminotetrahydroquinolin-derivat
ES1071332Y (es) Estante o parte de estante, desmontable
IT1391352B1 (it) Gruppo di presa, particolarmente per valigie, bauli e simili
ITLI20070010U1 (it) Il marziano, barbecue.
ITPR20080004A1 (it) Seggiola.
ITPO20080016A1 (it) Tricoceutica, prodotto tricoceutico.
FR2916326B3 (fr) La valise alimentaire.
ES1069539Y (es) Objeto de papiroflexia en lamina.
NL1033607A1 (nl) Bouwwerk.
FIU20070267U0 (fi) Istuin
FR2935319B1 (fr) Fourgonnette amenagee.
NL1036071C (nl) Zelfperforerende ordner.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A E 6A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2385 DE 20-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.